Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor primarily associated with asbestos exposure. Early detection of MPM is restricted by the long latency period until clinical presentation, the ineffectiveness of imaging techniques in early stage detection and the lack of non-invasive biomarkers with high sensitivity and specificity. In this study we used transcriptome data mining in order to determine which CLAUDIN (CLDN) genes are differentially expressed in MPM as compared to controls. Using the same approach we identified the interactome of the differentially expressed CLDN genes and assessed their expression profile. Subsequently, we evaluated the effect of tumor histology, asbestos exposure, CDKN2A deletion status, and gender on the gene expression level of the claudin interactome. We found that 5 out of 15 studied CLDNs (4, 5, 8, 10, 15) and 4 out of 27 available interactors (S100B, SHBG, CDH5, CXCL8) were differentially expressed in MPM specimens vs. healthy tissues. The genes encoding the CLDN-15 and S100B proteins present differences in their expression profile between the three histological subtypes of MPM. Moreover, CLDN-15 is significantly under-expressed in the cohort of patients with previous history of asbestos exposure. CLDN-15 was also found significantly underexpressed in patients lacking the CDKN2A gene. These results warrant the detailed in vitro investigation of the role of CDLN-15 in the pathobiology of MPM.

[1]  Paschalis-Adam Molyvdas,et al.  Transcriptional over-expression of chloride intracellular channels 3 and 4 in malignant pleural mesothelioma , 2015, Comput. Biol. Chem..

[2]  K. Gourgoulianis,et al.  Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[3]  P. Gosset,et al.  Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma. , 2015, Annals of diagnostic pathology.

[4]  C. Lim,et al.  Mesothelial cells in tissue repair and fibrosis , 2015, Front. Pharmacol..

[5]  M. Vyberg,et al.  The established and future biomarkers of malignant pleural mesothelioma. , 2015, Cancer treatment reviews.

[6]  V. Antony,et al.  Pleural mesothelial cells in pleural and lung diseases. , 2015, Journal of thoracic disease.

[7]  J. Creaney,et al.  Discovery of new biomarkers for malignant mesothelioma , 2015, Current Pulmonology Reports.

[8]  Qiang Li,et al.  Use of Proteins as Biomarkers and Their Role in Carcinogenesis , 2015, Journal of Cancer.

[9]  N. Pavlakis,et al.  Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales , 2014, British Journal of Cancer.

[10]  E. Taioli,et al.  Women with malignant pleural mesothelioma have a threefold better survival rate than men. , 2014, The Annals of thoracic surgery.

[11]  S. Amasheh,et al.  Tight junction physiology of pleural mesothelium , 2014, Front. Physiol..

[12]  G. Pinkus,et al.  Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology , 2014, Cancer cytopathology.

[13]  M. Fromm,et al.  Laurate Permeates the Paracellular Pathway for Small Molecules in the Intestinal Epithelial Cell Model HT-29/B6 via Opening the Tight Junctions by Reversible Relocation of Claudin-5 , 2014, Pharmaceutical Research.

[14]  M. Fromm,et al.  Erratum to: Laurate Permeates the Paracellular Pathway for Small Molecules in the Intestinal Epithelial Cell Model HT-29/B6 via Opening the Tight Junctions by Reversible Relocation of Claudin-5 , 2014, Pharmaceutical Research.

[15]  M. Fromm,et al.  Comparative analysis of theophylline and cholera toxin in rat colon reveals an induction of sealing tight junction proteins , 2014, Pflügers Archiv - European Journal of Physiology.

[16]  W. Thomas,et al.  Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009. , 2014, Cancer epidemiology.

[17]  U. Manne,et al.  The Chemokine CXCL8 in Carcinogenesis and Drug Response , 2013, ISRN oncology.

[18]  M. Kushima,et al.  Claudin-4 as a Marker for Distinguishing Malignant Mesothelioma From Lung Carcinoma and Serous Adenocarcinoma , 2013, International journal of surgical pathology.

[19]  N. Ordóñez Value of claudin-4 immunostaining in the diagnosis of mesothelioma. , 2013, American journal of clinical pathology.

[20]  Y. C. Lee,et al.  The continual search for ideal biomarkers for mesothelioma: the hurdles. , 2013, Journal of thoracic disease.

[21]  K. Gourgoulianis,et al.  Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma. , 2013, Gene.

[22]  M. Copin,et al.  M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo. , 2013, In vivo.

[23]  Christie S. Chang,et al.  The BioGRID interaction database: 2013 update , 2012, Nucleic Acids Res..

[24]  Ralf Herwig,et al.  The ConsensusPathDB interaction database: 2013 update , 2012, Nucleic Acids Res..

[25]  Stephen A. Williams,et al.  Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.

[26]  Duane H. Hamilton,et al.  Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. , 2012, Future oncology.

[27]  P. Rascoe,et al.  Molecular pathogenesis of malignant mesothelioma , 2012, Expert Reviews in Molecular Medicine.

[28]  F. Gemignani,et al.  A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. , 2012, Mutation research.

[29]  K. Gourgoulianis,et al.  Matrix metalloproteinases 2 and 9 increase permeability of sheep pleura in vitro , 2012, BMC Physiology.

[30]  K. Kiura,et al.  Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma , 2012, Cancer science.

[31]  Xiaowen Pang,et al.  S100B protein as a possible participant in the brain metastasis of NSCLC , 2012, Medical Oncology.

[32]  J. Dwyer,et al.  Jumping the barrier: VE‐cadherin, VEGF and other angiogenic modifiers in cancer , 2011, Biology of the cell.

[33]  B. Christensen,et al.  Epigenomics in Environmental Health , 2011, Front. Gene..

[34]  Y. Soini Claudins in lung diseases , 2011, Respiratory research.

[35]  M. Fromm,et al.  Tight junction proteins contribute to barrier properties in human pleura , 2011, Respiratory Physiology & Neurobiology.

[36]  B. Davidson The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma , 2011, Cytopathology : official journal of the British Society for Clinical Cytology.

[37]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[38]  S. Milatz,et al.  Claudin-3 acts as a sealing component of the tight junction for ions of either charge and uncharged solutes. , 2010, Biochimica et biophysica acta.

[39]  N. Reinmuth,et al.  Current data on predictive markers for anti-angiogenic therapy in thoracic tumours , 2010, European Respiratory Journal.

[40]  George M Yousef,et al.  Personalized Medicine: Marking a New Epoch in Cancer Patient Management , 2010, Molecular Cancer Research.

[41]  D. Waller,et al.  Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? , 2010, The Annals of thoracic surgery.

[42]  P. Morin,et al.  The claudins , 2009, Genome Biology.

[43]  Dean A Fennell,et al.  Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. , 2009, Cancer research.

[44]  A. Musk,et al.  Predicting survival in malignant mesothelioma , 2009, European Respiratory Journal.

[45]  J. Schleutker,et al.  Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. , 2009, The Journal of urology.

[46]  Sung-Liang Yu,et al.  Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. , 2009, American journal of respiratory and critical care medicine.

[47]  J. Gavard Breaking the VE‐cadherin bonds , 2008, FEBS letters.

[48]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[49]  Ralf Herwig,et al.  ConsensusPathDB—a database for integrating human functional interaction networks , 2008, Nucleic Acids Res..

[50]  J. Gutkind,et al.  VE-cadherin and claudin-5: it takes two to tango , 2008, Nature Cell Biology.

[51]  F. Orsenigo,et al.  Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5 , 2008, Nature Cell Biology.

[52]  K. Friedrich,et al.  Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. , 2008, Cancer research.

[53]  T. Nakano Current therapies for malignant pleural mesothelioma , 2008, Environmental health and preventive medicine.

[54]  S. Lonardi,et al.  Claudin‐4 in mesothelioma diagnosis , 2007, Histopathology.

[55]  B. Murer,et al.  Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions , 2007, Virchows Archiv.

[56]  I. Shih,et al.  The diagnostic role of claudins in serous effusions. , 2007, American journal of clinical pathology.

[57]  I. Shih,et al.  Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma , 2006, Clinical Cancer Research.

[58]  A. Olshen,et al.  Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.

[59]  Y. Soini,et al.  Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura , 2006, Journal of Clinical Pathology.

[60]  Michael C. Wendl,et al.  Argonaute—a database for gene regulation by mammalian microRNAs , 2005, BMC Bioinformatics.

[61]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[62]  J. Schulzke,et al.  Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells , 2005, Cell and Tissue Research.

[63]  R. Harpio,et al.  S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. , 2004, Clinical biochemistry.

[64]  M. Claeyssens,et al.  A hydrophobic platform as a mechanistically relevant transition state stabilising factor appears to be present in the active centre of all glycoside hydrolases , 2003, FEBS letters.

[65]  Torsten Schöneberg,et al.  Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells , 2002, Journal of Cell Science.

[66]  V. Antony,et al.  Polar production of interleukin-8 by mesothelial cells promotes the transmesothelial migration of neutrophils: role of intercellular adhesion molecule-1. , 2001, The Journal of infectious diseases.

[67]  M. Osanai,et al.  Claudins in cancer: bench to bedside , 2016, Pflügers Archiv - European Journal of Physiology.

[68]  Abderrahman Ouban,et al.  Claudins in human cancer: a review. , 2010, Histology and histopathology.

[69]  Erika Garay,et al.  Chapter 6 - Regulation of Claudins by Posttranslational Modifications and Cell-Signaling Cascades , 2010 .

[70]  P. Morin,et al.  Chapter 13 - Claudins in Cancer Biology , 2010 .

[71]  David J Sugarbaker,et al.  Tumorigenesis and Neoplastic Progression Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling , 2005 .

[72]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[73]  D. Lancet,et al.  Human Gene-Centric Databases at the Weizmann Institute of Science: GeneCards, UDB, CroW 21 and HORDE , 2003, Nucleic Acids Res..

[74]  M. Ward,et al.  Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. , 1999, Oncology research.